Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Oct. 31, 2017	$ 166,028	$ 163,931,079	$ (156,174,184)	$ 7,922,923		$ 7,922,923
Balance (in Shares) at Oct. 31, 2017	16,602,759
Stock option compensation to employees and directors		3,598,986		3,598,986		3,598,986
Stock options and warrants issued to consultants		254,090		254,090		$ 254,090
Common stock issued upon exercise of stock options	$ 398	(398)
Common stock issued upon exercise of stock options (in Shares)	39,816					10,600
Restricted stock award compensation to employee pursuant to stock incentive plan	$ 15,000	1,358,940		1,373,940		$ 1,373,940
Restricted stock award compensation to employee pursuant to stock incentive plan (in Shares)	1,500,000
Common stock issued to consultants	$ 53	14,949		15,002		15,002
Common stock issued to consultants (in Shares)	5,347
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198	$ 5,482	1,780,547		1,786,029		1,786,029
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198 (in Shares)	548,224
Issuance of noncontrolling interest in Certainty Therapeutics, Inc		68,974		68,974	$ (4,318)	64,656
Net loss			(8,693,532)	(8,693,532)	(158,032)	(8,851,564)
Balance at Jul. 31, 2018	$ 186,961	171,007,167	(164,867,716)	6,326,412	(162,350)	6,164,062
Balance (in Shares) at Jul. 31, 2018	18,696,146
Balance at Apr. 30, 2018	$ 168,504	165,288,632	(159,390,790)	6,066,346	(45,700)	6,020,646
Balance (in Shares) at Apr. 30, 2018	16,850,445
Stock option compensation to employees and directors		3,126,454		3,126,454		3,126,454
Stock options and warrants issued to consultants		127,939		127,939		127,939
Restricted stock award compensation to employee pursuant to stock incentive plan	$ 15,000	1,358,940		1,373,940		1,373,940
Restricted stock award compensation to employee pursuant to stock incentive plan (in Shares)	1,500,000
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198	$ 3,457	1,105,202		1,108,659		1,108,659
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198 (in Shares)	345,701
Net loss			(5,476,926)	(5,476,926)	(116,650)	(5,593,576)
Balance at Jul. 31, 2018	$ 186,961	171,007,167	(164,867,716)	6,326,412	(162,350)	6,164,062
Balance (in Shares) at Jul. 31, 2018	18,696,146
Balance at Oct. 31, 2018	$ 189,086	175,415,931	(170,170,209)	5,434,808	(251,377)	5,183,431
Balance (in Shares) at Oct. 31, 2018	18,908,632
Stock option compensation to employees and directors		2,808,910		2,808,910		2,808,910
Stock options and warrants issued to consultants		139,161		139,161		139,161
Common stock issued upon exercise of stock options	$ 400	102,100		102,500		$ 102,500
Common stock issued upon exercise of stock options (in Shares)	40,000					4,000
Restricted stock award compensation to employee pursuant to stock incentive plan		1,954,441		1,954,441		$ 1,954,441
Common stock issued pursuant to employee stock purchase plan	$ 54	18,506		18,560		18,560
Common stock issued pursuant to employee stock purchase plan (in Shares)	5,411
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198	$ 12,088	4,887,657		4,899,745		4,899,745
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198 (in Shares)	1,208,808
Net loss			(9,559,561)	(9,559,561)	(148,030)	(9,707,591)
Balance at Jul. 31, 2019	$ 201,628	185,326,706	(179,729,770)	5,798,564	(399,407)	5,399,157
Balance (in Shares) at Jul. 31, 2019	20,162,851
Balance at Apr. 30, 2019	$ 200,050	183,932,744	(177,589,742)	6,543,052	(373,387)	6,169,665
Balance (in Shares) at Apr. 30, 2019	20,005,075
Stock option compensation to employees and directors		784,246		784,246		784,246
Stock options and warrants issued to consultants		46,652		46,652		46,652
Common stock issued upon exercise of stock options	$ 100	22,600		22,700		22,700
Common stock issued upon exercise of stock options (in Shares)	10,000
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198	$ 1,478	540,464		541,942		541,942
Common stock issued in at-the-market offering, net of offering expenses of $264,186/$111,275/$141,140/$58,198 (in Shares)	147,776
Net loss			(2,140,028)	(2,140,028)	(26,020)	(2,166,048)
Balance at Jul. 31, 2019	$ 201,628	$ 185,326,706	$ (179,729,770)	$ 5,798,564	$ (399,407)	$ 5,399,157
Balance (in Shares) at Jul. 31, 2019	20,162,851